Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson
Medtronic
AstraZeneca
Baxter
McKesson

Last Updated: May 31, 2023

LEVOCARNITINE SF Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


When do Levocarnitine Sf patents expire, and when can generic versions of Levocarnitine Sf launch?

Levocarnitine Sf is a drug marketed by Novitium Pharma and is included in one NDA.

The generic ingredient in LEVOCARNITINE SF is levocarnitine. There are four drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the levocarnitine profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Levocarnitine Sf

A generic version of LEVOCARNITINE SF was approved as levocarnitine by HIKMA on March 29th, 2001.

  Try a Trial

Summary for LEVOCARNITINE SF
Drug patent expirations by year for LEVOCARNITINE SF
Recent Clinical Trials for LEVOCARNITINE SF

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Children's Oncology GroupPhase 3
University of California, IrvineEarly Phase 1
Children's Hospital of Orange CountyEarly Phase 1

See all LEVOCARNITINE SF clinical trials

Pharmacology for LEVOCARNITINE SF
Drug ClassCarnitine Analog

US Patents and Regulatory Information for LEVOCARNITINE SF

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novitium Pharma LEVOCARNITINE SF levocarnitine SOLUTION;ORAL 211676-002 Aug 14, 2019 AA RX No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Medtronic
Boehringer Ingelheim
Colorcon
Baxter
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.